首页> 外文期刊>Journal of inflammation. >The effect of substance P on asthmatic rat airway smooth muscle cell proliferation, migration, and cytoplasmic calcium concentration in vitro
【24h】

The effect of substance P on asthmatic rat airway smooth muscle cell proliferation, migration, and cytoplasmic calcium concentration in vitro

机译:P物质对哮喘大鼠气道平滑肌细胞增殖,迁移和细胞质钙浓度的影响

获取原文
           

摘要

Airway remodeling and airway hyper-responsiveness are prominent features of asthma. Neurogenic inflammation participates in the development of asthma. Neurokinin substance P acts by binding to neurokinin-1 receptor (NK-1R). Airway smooth muscle cells (ASMC) are important effector cells in asthma. Increases in ASMC proliferation, migration, and cytoplasmic Ca2+ concentration are critical to airway remodeling and hyper-responsiveness. The effects of substance P on ASMC were investigated in Wistar rats challenged with a previously described asthmatic rat model. To exclude possible influences from other factors, the role of substance P was also investigated in primary cultured rat ASMC. Substance P and WIN62577-induced changes in cytoplasmic Ca2+ concentration were observed by fluorescence microscopy, and expression of Ca2+ homeostasis-regulating genes was assessed with real-time PCR. We found that cytoplasmic Ca2+ concentration increased in normal rat ASMC treated with substance P, but decreased in asthmatic rat ASMC treated with WIN62577, an antagonist of NK-1R. Real-time PCR analysis revealed increased Serca2 mRNA expression but decreased Ip3r mRNA expression after WIN62577 treatment in asthmatic rat ASMC. Flow cytometric analysis (FCM) revealed that most asthmatic rat ASMC stayed at G1 phase after combined treatment with WIN62577 and IL-13 in vitro. Transwell analysis suggested that ASMC migration was reduced after WIN62577 treatment. Therefore, we conclude that NK-1R is related to asthma mechanisms and a NK-1R antagonist downregulates calcium concentration in asthmatic ASMC by increasing Serca2 mRNA and decreasing Ip3r mRNA expression. The NK-1R antagonist WIN62577 inhibited ASMC IL-13-induced proliferation and ASMC migration in vitro and therefore may be a new therapeutic option in asthma.
机译:气道重塑和气道高反应性是哮喘的突出特征。神经源性炎症参与哮喘的发展。神经激肽P通过与神经激肽1受体(NK-1R)结合而起作用。气道平滑肌细胞(ASMC)是哮喘中重要的效应细胞。 ASMC增殖,迁移和细胞质Ca2 +浓度的增加对于气道重塑和高反应性至关重要。在先前描述的哮喘大鼠模型攻击的Wistar大鼠中研究了P物质对ASMC的作用。为了排除其他因素的可能影响,还研究了P物质在原代培养的大鼠ASMC中的作用。通过荧光显微镜观察物质P和WIN62577诱导的细胞质Ca2 +浓度变化,并通过实时PCR评估Ca2 +稳态调节基因的表达。我们发现,用P物质处理的正常大鼠ASMC中细胞质Ca2 +浓度升高,而用NK-1R拮抗剂WIN62577处理的哮喘大鼠ASMC中细胞质Ca2 +浓度降低。实时PCR分析显示,哮喘大鼠ASMC经过WIN62577治疗后,Serca2 mRNA表达增加,而Ip3r mRNA表达降低。流式细胞仪分析(FCM)显示,大多数哮喘大鼠ASMC在体外与WIN62577和IL-13联合治疗后停留在G1期。 Transwell分析表明,WIN62577处理后ASMC迁移减少。因此,我们得出结论,NK-1R与哮喘机制有关,并且NK-1R拮抗剂通过增加Serca2 mRNA和降低Ip3r mRNA表达来下调哮喘ASMC中的钙浓度。 NK-1R拮抗剂WIN62577在体外抑制ASMC IL-13诱导的增殖和ASMC迁移,因此可能是哮喘的新治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号